| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.5M | -30.0% | +3.5% |
| SG&A Expense | $1.1M | -50.6% | -32.5% |
| Operating Income | -$2.6M | +40.6% | +15.7% |
| Net Income | -$3.0M | +43.1% | +3.1% |
| EPS (Basic) | -$2.98 | +67.2% | -831.3% |
| EPS (Diluted) | -$2.98 | +67.2% | -831.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $5.8M | -5.4% | -21.1% |
| Current Assets | $6.4M | +0.4% | -15.6% |
| Total Assets | $6.8M | +0.0% | -17.0% |
| Current Liabilities | $2.2M | -73.8% | +0.1% |
| Stockholders' Equity | $4.6M | +375.2% | -23.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$11.6M | — | — |
| Financing Cash Flow | $11.7M | — | — |